The antiviral prophylaxis of post-transplant lymphoproliferative disorder.
Davis
C L
CL
Division of Nephrology and Transplantation Services, University of Washington Medical Center, Seattle 98195-6174, USA.
D000284:Administration, Oral; D000914:Antibodies, Viral / Q000097:blood; D000918:Antibody Specificity; D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology; D004279:DNA, Viral / Q000032:analysis; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D015774:Ganciclovir / Q000627:therapeutic use; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007167:Immunotherapy; D008232:Lymphoproliferative Disorders / Q000517:prevention & control* / Q000821:virology; D016377:Organ Transplantation / Q000009:adverse effects*; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology
D000914:Antibodies, Viral; D000998:Antiviral Agents; D004279:DNA, Viral; D007074:Immunoglobulin G; D015774:Ganciclovir